Brief: Odonate Therapeutics Announces Positive Results From Phase 3 Study Of Tesetaxel To Treat Metastatic Breast Cancer

Odonate

24/08/2020 12:46

Aug 24 (Reuters) - Odonate Therapeutics Inc  ODT.O :
    * ODONATE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS
FROM
CONTESSA, A PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH
METASTATIC BREAST CANCER
    * ODONATE THERAPEUTICS INC - CONTESSA ACHIEVED PRIMARY
ENDPOINT
    * ODONATE - MEDIAN PFS WAS 9.8 MONTHS FOR TESETAXEL PLUS A
REDUCED
DOSE OF CAPECITABINE VERSUS 6.9 MONTHS FOR APPROVED DOSE OF
CAPECITABINE ALONE
    * ODONATE THERAPEUTICS, ON CONTESSA, SAYS RISK OF DISEASE
PROGRESSION OR DEATH WAS REDUCED BY 28.4% FOR TESETAXEL PLUS A
REDUCED DOSE OF CAPECITABINE
    * ODONATE - TESETAXEL PLUS CAPECITABINE WAS ASSOCIATED WITH
A
MANAGEABLE SIDE EFFECT PROFILE CONSISTENT WITH FINDINGS FROM
PREVIOUS CLINICAL STUDIES
    * ODONATE THERAPEUTICS INC - FINAL ANALYSIS OF OS IS
EXPECTED TO
OCCUR IN 2022 FOR CONTESSA

Source text for Eikon:  ID:nBw7vg3Lna 
Further company coverage:  ODT.O 

 ((Reuters.Briefs@thomsonreuters.com;))